BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Goher Rahbour, Janindra Warusavitarne, Ailsa L. Hart, Philip J. Tozer, Mohammad R. Ullah, Gregory P. Thomas, Simon M. Gabe, Stella C. Knight, Hafid O. Al-Hassi, Carolynne J. Vaizey. Pilot study of immunological factors in non-inflammatory bowel disease enterocutaneous fistulasInternational Journal of Surgery 2017; 41: 127 doi: 10.1016/j.ijsu.2017.03.079
2
Uwe Wollina, Gunter Haroske. Pyoderma gangraenosumCurrent Opinion in Rheumatology 2011; 23(1): 50 doi: 10.1097/BOR.0b013e328341152f
3
Afsaneh Alavi, Lars E. French, Mark D. Davis, Alain Brassard, Robert S. Kirsner. Pyoderma Gangrenosum: An Update on Pathophysiology, Diagnosis and TreatmentAmerican Journal of Clinical Dermatology 2017; 18(3): 355 doi: 10.1007/s40257-017-0251-7
4
Stephan R. Vavricka, Alain Schoepfer, Michael Scharl, Peter L. Lakatos, Alexander Navarini, Gerhard Rogler. Extraintestinal Manifestations of Inflammatory Bowel DiseaseInflammatory Bowel Diseases 2015; 21(8): 1982 doi: 10.1097/MIB.0000000000000392
5
Hakim Ben Abdallah, Karsten Fogh, Rikke Bech. Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi‐systematic reviewInternational Wound Journal 2019; 16(2): 511 doi: 10.1111/iwj.13067
6
A. Agarwal, J. M. Andrews. Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapyAlimentary Pharmacology & Therapeutics 2013; 38(6): 563 doi: 10.1111/apt.12431
7
Clóvis Luíz Konopka, Geórgia Andrade Padulla, Michele Purper Ortiz, Anderson Kahl Beck, Mariana Rechia Bitencourt, Diogo Chagas Dalcin. Pioderma Gangrenoso: um Artigo de RevisãoJornal Vascular Brasileiro 2013; 12(1): 25 doi: 10.1590/S1677-54492013000100006
8
Simone Garcovich, Clara De Simone, Emilio Berti, Angelo Valerio Marzano. Drug management of neutrophilic dermatosesExpert Review of Clinical Pharmacology 2017; 10(10): 1119 doi: 10.1080/17512433.2017.1356719
9
Maddalena Zippi, Roberta Pica, Daniela De Nitto, Paolo Paoluzi. Biological therapy for dermatological manifestations of inflammatory bowel diseaseWorld Journal of Clinical Cases 2013; 1(2): 74-78 doi: 10.12998/wjcc.v1.i2.74
10
Charlotte Hurabielle, Pierre Schneider, Clotilde Baudry, Martine Bagot, Matthieu Allez, Manuelle Viguier. Certolizumab pegol – A new therapeutic option for refractory disseminated pyoderma gangrenosum associated with Crohn’s diseaseJournal of Dermatological Treatment 2016; 27(1): 67 doi: 10.3109/09546634.2015.1034075
11
G. Andrisani, L. Guidi, A. Papa, A.E. Potenza, D. Cervelli, A. Armuzzi. A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: Infliximab and surgeryJournal of Crohn's and Colitis 2013; 7(5): 421 doi: 10.1016/j.crohns.2012.07.021
12
Bruno Rafael Ramos de Mattos, Maellin Pereira Gracindo Garcia, Julia Bier Nogueira, Lisiery Negrini Paiatto, Cassia Galdino Albuquerque, Caique Lopes Souza, Luís Gustavo Romani Fernandes, Wirla Maria da Silva Cunha Tamashiro, Patricia Ucelli Simioni. Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological TreatmentsMediators of Inflammation 2015; 2015: 1 doi: 10.1155/2015/493012
13
P. Al Ghazal, J. Dissemond. Multilokuläres Pyoderma gangraenosum nach UterusresektionDer Chirurg 2012; 83(3): 254 doi: 10.1007/s00104-011-2259-5
14
I. Sick, T. Ruzicka. Pyoderma gangraenosumJournal für Ästhetische Chirurgie 2011; 4(1): 7 doi: 10.1007/s12631-010-0105-0
15
Ignasi Figueras Nart, Sara Martín-Sala, Alba Álvarez-Abella, Anna Jucglà Serra. Pioderma gangrenosoPiel 2012; 27(3): 132 doi: 10.1016/j.piel.2011.10.012
16
F. Argüelles-Arias, L. Castro-Laria, T. Lobatón, M. Aguas-Peris, M. Rojas-Feria, M. Barreiro-de Acosta, P. Soto-Escribano, M. Calvo-Moya, D. Ginard-Vicens, M. Chaparro-Sánchez, M. Hernández-Durán, B. Castro-Senosiain, A. Fernández-Villaverde, V. García-Sánchez, E. Domínguez-Muñoz, A. Caunedo-Álvarez, J. M. Herrerías-Gutiérrez. Characteristics and Treatment of Pyoderma Gangrenosum in Inflammatory Bowel DiseaseDigestive Diseases and Sciences 2013; 58(10): 2949 doi: 10.1007/s10620-013-2762-2
17
Raj Patel, John M Cafardi, Nital Patel, Naveed Sami, Jennifer A Cafardi. Tumor necrosis factor biologics beyond psoriasis in dermatologyExpert Opinion on Biological Therapy 2011; 11(10): 1341 doi: 10.1517/14712598.2011.590798
18
Fatima McKenzie, Megan Arthur, Alex G. Ortega-Loayza. Pyoderma Gangrenosum: What Do We Know Now?Current Dermatology Reports 2018; 7(3): 147 doi: 10.1007/s13671-018-0224-y
19
Fatima McKenzie, Devin Cash, Angela Gupta, Laurel W. Cummings, Alex G. Ortega-Loayza. Biologic and small-molecule medications in the management of pyoderma gangrenosumJournal of Dermatological Treatment 2019; 30(3): 264 doi: 10.1080/09546634.2018.1506083
20
Ahmed Hadi, Mark Lebwohl. Clinical features of pyoderma gangrenosum and current diagnostic trendsJournal of the American Academy of Dermatology 2011; 64(5): 950 doi: 10.1016/j.jaad.2010.01.049
21
Robert Löfberg, Edouard V. Louis, Walter Reinisch, Anne M. Robinson, Martina Kron, Anne Camez, Paul F. Pollack. Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohnʼs disease: Results from CAREInflammatory Bowel Diseases 2012; 18(1): 1 doi: 10.1002/ibd.21663
22
János Fehér, Gabriella Lengyel. The effectivity and safety of the biological therapy with adalimumabOrvosi Hetilap 2009; 150(26): 1215 doi: 10.1556/oh.2009.28681
23
Luciano Alessandroni, Andrea Scotti. Crohn’s Disease2010; : 221 doi: 10.1007/978-88-470-1472-5_19
24
Shintaro Sagami, Yoshitaka Ueno, Shinji Tanaka, Kenta Nagai, Ryohei Hayashi, Kazuaki Chayama. Successful Use of Adalimumab for Treating Pyoderma Gangrenosum with Ulcerative Colitis under Corticosteroid-tapering ConditionsInternal Medicine 2015; 54(17): 2167 doi: 10.2169/internalmedicine.54.4853
25
José Mª Mir Bonafé, Emilia Fernández López, Gonzalo Nieto González, Pablo De Unamuno Pérez. Manifestaciones cutáneas en enfermedad inflamatoria intestinalPiel 2011; 26(9): 451 doi: 10.1016/j.piel.2011.03.017
26
E.M. DeFilippis, S.R. Feldman, W.W. Huang. The genetics of pyoderma gangrenosum and implications for treatment: a systematic reviewBritish Journal of Dermatology 2015; 172(6): 1487 doi: 10.1111/bjd.13493
27
Irune Cariñanos, Manuel Barreiro-De Acosta, Eugeni Domènech. Adalimumab for pyoderma gangrenosum associated with inflammatory bowel diseaseInflammatory Bowel Diseases 2011; 17(12): E153 doi: 10.1002/ibd.21723
28
I. Sick, B. Trautner, T. Ruzicka. Chirurgische Therapie beim Pyoderma gangraenosumDer Hautarzt 2012; 63(7): 577 doi: 10.1007/s00105-011-2269-8
29
Vishal Ghevariya, Shashideep Singhal, Sury Anand. The skin: a mirror to the gutInternational Journal of Colorectal Disease 2013; 28(7): 889 doi: 10.1007/s00384-012-1637-x